PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth near Biotechnology median of 100.00%. Charlie Munger would expect industry-level profitability trends are driving results.
-121.69%
Negative operating income growth while Biotechnology median is 1.31%. Seth Klarman would check if structural or cyclical issues are at play.
-139.60%
Negative net income growth while Biotechnology median is -2.65%. Seth Klarman would investigate factors dragging net income down.
-131.82%
Negative EPS growth while Biotechnology median is 0.56%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-131.82%
Negative diluted EPS growth while Biotechnology median is 0.71%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while Biotechnology median is -13.59%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-31.70%
Negative FCF growth while Biotechnology median is -12.51%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.37%
OCF/share CAGR of 95.37% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
75.95%
5Y OCF/share growth exceeding 1.5x Biotechnology median of 2.46%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
7.00%
Below 50% of Biotechnology median. Jim Chanos would suspect fundamental problems or inadequate monetization of sales in the near term.
81.58%
Net income/share CAGR exceeding 1.5x Biotechnology median of 28.35% over a decade. Joel Greenblatt might see a standout compounder of earnings.
47.75%
5Y net income/share CAGR > 1.5x Biotechnology median of 23.55%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-122.09%
Negative 3Y CAGR while Biotechnology median is 36.23%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-94.45%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
58.16%
5Y equity/share CAGR of 58.16% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-73.50%
Negative 3Y equity/share growth while Biotechnology median is -51.77%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-21.56%
Negative BV/share change while Biotechnology median is -9.95%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.90%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
60.05%
We slightly increase R&D while Biotechnology is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
231.77%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.